Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 11 Feb 2016
At a glance
- Drugs Olaparib (Primary)
- Indications Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 09 Oct 2015 Planned end date changed from 1 Feb 2018 to 1 Feb 2019, as reported by ClinicalTrials.gov.
- 09 Oct 2015 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017, as reported by ClinicalTrials.gov.
- 05 Sep 2014 New trial record